Alterations in Eotaxin,Monocyte Chemoattractant Protein-4,Interleukin-5,and Interleukin-13 After Systemic Steroid Treatment for Nasal Polyps

Abstract

OBJECTIVE: To determine alterations in Th2 chemokines eotaxin and monocyte chemoattractant protein-4 (MCP-4), and cytokines interleukin-5 (IL-5) and interleukin-13 (IL-13), in nasal polyps (NP) after steroid treatment.

STUDY DESIGN: Cytokine/chemokine levels were measured in NP before and after steroid therapy and compared to control sinus mucosa.

RESULTS: Twenty-one patients (control = 7, NP = 14) were enrolled. Eotaxin and MCP-4 were significantly higher than control tissue (P = 0.004 and 0.003). All four mediators decreased after steroid treatment (P < 0.03). IL-5 and IL-13 in untreated polyps were not significantly different from controls. Patients showed clinical improvement according to SNOT-20 scores (average presteroid score 19, post-steroid score 13) and endoscopic grading (1.75 each side presteroid, 1.13 poststeroid).

CONCLUSIONS: Steroids significantly decreased all cytokine/chemokine levels, but the impact on Th2 chemokines was of a much greater magnitude.

SIGNIFICANCE: Novel approaches to block inflammatory mediators, particularly Th2 chemokines, may lead to better control of nasal polyposis in the future.

Get full access to this article

View all access options for this article.

References

Barnes

Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002; 42: 81–98.

Kumar

Herbert

Yang

, et al. Role of interleukin-13 in eosinophil accumulation and airway remodeling in a mouse model of chronic asthma. Clin Exp Allergy 2002; 32(7): 1104–11.

Durham

Ying

Varney

Cytokine mRNA expression for IL-3, IL-4, IL-5, and GM-CSF in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilia. J Immunol 1992; 148: 2390–4.

Gutiettez-Ramos

, et al. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000; 177: 31–42.

Ponath

Cloning of the human eosinophil chemoattractant, eotaxin expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97: 604–12.

Ying

, et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3 and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999; 163: 2160–7.

Marple

Allergic fungal rhinosinusitis: Current theories and management strategies. Laryngoscope 2001; 111: 1006–19.

Schubert

Goetz

Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up. J Allergy Clin Immunol 1998; 102(3): 395–402.

Kupferberg

Bent

Kuhn

Prognosis for allergic fungal sinusitis. Otolaryngol Head Neck Surg 1997; 117: 35–41.

10.

Anon

, editor. Report of the Rhinosinusitis Task Force Committee Meeting. Otolaryngol Head Neck Surg 1997; 117(3) Part 2.

11.

Bradford

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.

12.

Jahnsen

Haye

Gran

, et al. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999; 163(3): 1545–51.

13.

Shin

Park

Jeon

, et al. Quantitative analysis of eotaxin and RANTES messenger RNA in nasal polyps: Association of tissue and nasal eosinophils. Laryngoscope 2000; 110(8): 1353–7.

14.

Kramer

Ostertag

Pfrogner

Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis. Laryngoscope 2000; 110: 1056–62.

15.

Teran

CCL chemokines and asthma. Immunol Today 2000; 21(5): 235–42.